Overview

Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients

Status:
Active, not recruiting

Trial end date:
2021-02-28

Target enrollment:

Participant gender:

Summary

Probands with MCI are at high risk to develop Alzheimer´s dementia (AD). Simvastatin may lower the production of Amyloid, a hallmark of AD in the brain. The primary hypothesis of the study is that 60 mg Simvastatin significantly reduces the Clinical Dementia Rating -Sum of boxes (CDR-SOB) in individuals with MCI as compared to MCI receiving placebo or 20 mg Simvastatin

Phase:

Phase 4

Details

Lead Sponsor:

Charite University, Berlin, Germany

Collaborator:

German Federal Ministry of Education and Research

Treatments:

Simvastatin